Japan Exports to U.S. Rebound in November as Tariff Impact Eases, Boosting BOJ Rate Hike Expectations 
Bank of Korea Downplays Liquidity’s Role in Weak Won and Housing Price Surge 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Silver Prices Hit Record High as Safe-Haven Demand Surges Amid U.S. Economic Uncertainty 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Asian Stocks Edge Higher as Tech Recovers, U.S. Economic Uncertainty Caps Gains 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Trump Orders Blockade of Sanctioned Oil Tankers, Raising Venezuela Tensions and Oil Prices 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Oil Prices Rebound as Trump Orders Blockade of Sanctioned Venezuelan Tankers 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
U.S. Dollar Slips Near Two-Month Low as Markets Await Key Jobs Data and Central Bank Decisions 
Asian Stocks Slide as AI Valuation Fears and BOJ Uncertainty Weigh on Markets 
Eli Lilly and Company has acquired biopharmaceutical firm Dice Therapeutics for $2.4 billion, fortifying its position in immune-related disease treatments. The strategic move expands Lilly's portfolio with Dice's cutting-edge oral drugs for autoimmune conditions.
Eli Lilly said that the deal with Dice Therapeutics is worth $2.4 billion, and it was agreed that it would pay $48 per share in cash for the purchase. This is equivalent to a 40% premium where the latter's shares closed last Friday.
As per CNBC, the buyout is expected to be completed within the third quarter of this year. With the announcement of the negotiations, the stock price of Eli Lilly reportedly shot up by more than one percent in the early morning trading today. Dice Therapeutics' share price also increased by more than 37%.
Dice Therapeutics is known to use proprietary technology to create new oral drug treatments for various autoimmune diseases. These are illnesses wherein the immune system attacks the person's own cells instead of protecting them as they should.
Currently, there are over 100 known kinds of autoimmune diseases, and the most well-known are lupus, Crohn's disease, rheumatoid arthritis, and ulcerative colitis. The San Francisco-based pharma company is a leading drugmaker to help treat such conditions. Aside from these medications, it is also in the middle of developing another drug for psoriasis which is an immune-related skin condition.
"In combination with its novel technology and expertise in drug discovery, DICE's talented workforce and passion for innovation will enhance our efforts to make life better for people living with devastating autoimmune diseases," Lilly USA's executive vice president, president of Immunology, and chief customer officer, Patrik Jonsson, said in a press release. "We welcome DICE colleagues to Lilly and, together, we can tackle the challenges ahead in finding new treatments for patients with significant unmet medical needs."
Dice Therapuetics' CEO, Kevin Judice, Ph.D., further said, "We are eager to see our pipeline, including our oral IL-17 inhibitors, DC-806 and DC-853, benefit from Lilly's resources and global reach and I'm excited by the prospect of watching these two talented teams in a united quest for scientific innovation."
Photo by: Eli Lilly Press Release
